A CDMO specializing in mRNA medicines and vaccines, founded by Axcelead (Japan's first drug discovery platform) and Arcturus Therapeutics (a US mRNA company). In 2023, ARCALIS opened a GMP mRNA drug substance facility in Japan, and in 2024 achieved the world's first commercial production of a self-amplifying mRNA COVID-19 vaccine, supporting clients from early research through commercial production across rare diseases, oncology, regenerative medicine and genome editing.
Chưa có bình luận nào.
Để lại đánh giá & nhận xét